Citi lowered the firm’s price target on Arvinas (ARVN) to $9.50 from $10 and keeps a Neutral rating on the shares. The firm says Pfizer’s decision to no longer pursue vepdeg Phase 3 combos has given Arvinas’ pipeline new important.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Strategic Reprioritization and Future Potential Drive Buy Rating for Arvinas Holding Company
- Arvinas downgraded to Hold from Buy at Truist
- Arvinas Earnings Call: Clinical Progress and Strategic Shifts
- Arvinas price target lowered to $10 from $20 at BMO Capital
- Arvinas price target lowered to $24 from $81 at H.C. Wainwright